A Phase 4 interventional study of Myo-inositol in Sterility and Infertility, sponsored by American University of Beirut Medical Center. Recruiting at 1 site in Lebanon. Open to female participants aged 18 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by American University of Beirut Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing inositol in Infertility — 1 open to participants now, 1 under way, none of them phase 3. Inositol · Infertility.
Among the 10 studies testing inositol in Infertility, this one is the 6th largest by planned enrollment, is the only one that started in 2017, is one of 2 in phase 4, and was the 5th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 10 studies testing inositol in Infertility is open now, in 1 country.
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 18 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 3 · Phase 4 2
First in 2010; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 118 across the 10 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 7 most frequent:
American University of Beirut Medical Center is the lead sponsor of 158 studies on the registry; 24 are open to participants now.
American University of Beirut Medical Center has 6 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing inositol in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective comparative randomized controlled study investigating the effect of Myo-Inositol-based co-treatment on oocyte quality measures in women with PCOS.
Polycystic Ovary Syndrome is the most common cause of chronic anovulation in women. Women with PCOS undergoing IVF are at an increased risk for developing both multiple gestation and ovarian hyperstimulation syndrome (OHSS). Since insulin resistance and hyperinsulinemia have been implicated in the pathophysiology of the disorder, the administration of metformin before or during an IVF cycle has been practiced for years in an attempt to improve follicular parameters necessary for reproductive success. Recently, a growing body of evidence has implicated alternative insulin sensitizing drugs, namely Myo-Inositol, in improving various manifestations of the disorder in this women population. Little has been done to evaluate the effect of Myo-Inositol co-treatment on the reproductive performance of PCOS women undergoing Assisted Reproductive Technologies (ART). In this prospective comparative randomized controlled study, women will be randomized into two groups: Women in the control group will receive folic acid daily. Women in the study group will receive Myo-Inositol, in combination with alpha- lipoic acid and cysteine, per day plus folic acid supplemented daily along with ovarian stimulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid
Drug: Myo-inositol
Standard care: 400 ug of Folic acid
Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
Also known as: Celine
Oocyte yield
Time frame: 1 day from ovum pick up
Maturation rate
Time frame: 1 day from ovum pick up
Fertilization rate
Time frame: 16-18 hours post insemination
Blood profile (fasting sugar and insulin levels, Testosterone, Sex Hormone-Binding protein, DHEAs, and Androstenedione)
Time frame: Prior to and 6 weeks post enrollment
Number of gonadotropin ampules
Time frame: 1 day from oocyte maturation trigger
Obstetrical outcome (preterm birth)
Time frame: From 24 to 36 weeks gestation
Obstetrical outcome (low birth weight)
Time frame: From 24 to 36 weeks gestation
Obstetrical outcome (gestational diabetes)
Time frame: From 24 to 36 weeks gestation
Obstetrical outcome (preeclampsia)
Time frame: From 24 to 36 weeks gestation
Obstetrical outcome (admission to neonatal intensive care)
Time frame: From 24 to 36 weeks gestation
Number of stimulation days
Time frame: 1 day from oocyte maturation trigger
Embryo quality
Time frame: 3 to 5 days from ovum pick up
Miscarriage rate
Time frame: 7 weeks post LMP
Ongoing pregnancy
Time frame: 20 weeks post LMP
Live birth rate
Time frame: 24 to 42 weeks gestation
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2017 (actual). Primary completion is estimated for Dec 2023, 81 months after the start.
Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 81 months is above that.
Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inositol
American University of Beirut Medical Center →